Brian Goff, Agios CEO
In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo royalties for $131M
Almost two years after Agios sold its oncology unit to French pharma Servier in a $1.8 billion deal, Agios is letting go of its last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
